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Summary
Background—Periostin is highly expressed in eosinophilic esophagitis (EoE), but has not been 
extensively studied as a non-invasive biomarker.
Aim—To assess whether serum periostin distinguished EoE from controls at baseline, had utility 
for monitoring treatment response, or was associated with IL-13 levels.
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Methods—This was a sub-analysis of a prospective cohort study of adults undergoing outpatient 
upper endoscopy. Incident cases of EoE were diagnosed per consensus guidelines. Controls were 
subjects with either GERD or dysphagia without EoE. EoE patients were treated with swallowed/
topical steroids and had repeat endoscopy/biopsy. Serum periostin levels for cases and controls 
were compared at baseline, and pre/post-treatment levels were compared for cases. Serum IL-13 
and tissue expression of periostin were also assessed.
Results—A total of 61 incident EoE cases and 87 controls were analyzed. Despite a marked 
increase in tissue periostin expression in cases, the median baseline serum periostin level was only 
slightly higher in cases than controls (22.1 ng/mL vs 20.7; p=0.04); there was no change in post-
treatment levels. There was also no difference in serum periostin for cases by histologic response 
or atopic status. There was a strong trend towards higher serum IL-13 levels in cases in the highest 
periostin quartile (57.1 pg/mL vs 2.6; p=0.07).
Conclusions—Serum periostin levels were similar in cases and controls, and there were no 
changes post-treatment. Given elevated IL-13 levels in the EoE patients with the highest periostin 
levels, future studies could explore periostin as a biomarker in EoE, perhaps in the setting of anti-
IL-13 therapy.
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Introduction
Eosinophilic esophagitis (EoE) is a clinicopathologic condition characterized clinically by 
symptoms of esophageal dysfunction and histologically by eosinophilic infiltration of the 
esophageal mucosa,1, 2 and the increasing incidence is outpacing recognition.3 Diagnosis of 
EoE currently requires an invasive procedure, upper endoscopy with biopsy, to obtain tissue 
for histologic analysis and quantification of esophageal eosinophil counts.1, 2 Similarly, after 
treatment is prescribed, repeat endoscopy is required to monitor disease activity as clinical 
symptoms do not always correlate with biopsy results.4–6 Because of this burden of 
diagnosis and monitoring,7 non-invasive biomarkers would have a valuable role. While there 
is intense research in biomarker discovery in EoE, to date results regarding serum,8–15 
saliva,16 stool,8, 9 and respiratory17, 18 biomarkers have been mixed and none are routinely 
used in clinical care.19
Periostin is an extracellular matrix protein that is present in the esophageal epithelium, is 
highly expressed in patients with EoE, and is induced by IL-13.20–22 It is thought to 
facilitate eosinophil tissue infiltration by promoting eosinophil adhesion to fibronectin.23 
Therefore, it may be a promising marker of EoE. With the exception of a clinical trial that 
assessed serum periostin levels in EoE patients before and after treatment with an anti-IL-13 
monoclonal antibody13 and an abstract assessing a series of EoE cases,24 serum periostin 
has not been assessed as a biomarker for either diagnosis or monitoring of EoE. However, 
there has been experience using periostin levels to direct treatment of asthma with anti-IL-13 
medications,25–27 and assays to measure periostin in serum have now made it possible to 
examine this issue in depth in EoE.
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The aims of this study were to determine the feasibility of measuring serum periostin, assess 
whether it distinguishes EoE from controls at baseline, investigate its utility for monitoring 
EoE after treatment, and evaluate associations between periostin and IL-13 levels. We 
hypothesized that serum periston levels would be higher in EoE cases as compared to non-
EoE controls, and that levels would decrease after successful treatment of EoE.
Materials and Methods
Study design and case definitions
This was a sub-analysis of a prospective cohort study conducted at University of North 
Carolina from July, 2011 through December, 2013. Full details of the study design have 
been previously described.28–32 In brief, patients aged 18–80 years who were undergoing 
outpatient upper endoscopy for evaluation of symptoms of esophageal dysfunction (e.g. 
dysphagia, food impaction, heartburn, reflux, chest pain) were consecutively enrolled. 
Informed consent, including consent for future use of stored specimens, was obtained prior 
to the endoscopy. Exclusion criteria were: a known diagnosis of EoE or a different 
eosinophilic gastrointestinal disorder (EGID), GI bleeding, active anticoagulation, known 
esophageal cancer, prior esophageal surgery, known esophageal varices, medical instability 
or multiple comorbidities precluding enrollment in the clinical opinion of the endoscopist, or 
inability to read or understand the consent form. This study was approved by the UNC 
Institutional Review Board and registered on clinicaltrials.gov (NCT 01988285)
EoE cases were diagnosed by consensus guidelines.1, 2 Cases had to have at least one typical 
symptom of esophageal dysfunction and ≥15 eosinophils per high-power field (eos/hpf) on 
esophageal biopsy after an 8 week PPI trial (20–40 mg twice daily of any of the available 
agents, prescribed at the discretion of the clinician); other causes of esophageal eosinophilia 
also had to be excluded. Controls were subjects who did not meet clinical or histologic 
criteria for EoE after endoscopy and biopsy. Subjects with PPI-responsive esophageal 
eosinophilia (PPI-REE)33, 34 were not included in this study.
Clinical data and patient follow-up
Demographics, symptoms, concomitant atopic diseases, indications for endoscopy, and 
endoscopic findings were recorded using a standardized case report form. Research-protocol 
esophageal biopsies were obtained (two from the proximal, one from the mid, and two from 
the distal esophagus) to maximize EoE diagnostic sensitivity,35, 36 and research-protocol 
gastric and duodenal biopsies were also collected to exclude concomitant eosinophilic 
gastroenteritis. Additional clinical biopsies could be taken as indicated at the discretion of 
the endoscopist. The study pathologists quantified the esophageal eosinophil counts using 
our previously validated technique.37 Slides were masked to case/control status, digitized, 
and reviewed with Aperio ImageScope (Aperio Technologies, Vista, CA). Five microscopy 
fields from each of the five biopsies were examined to determine the maximum eosinophil 
density (eosinophils/mm2 [eos/mm2]). To compare data with prior studies, eosinophil 
density was converted to an eosinophil count (eos/hpf) using a hpf size of 0.24 mm2, the 
most commonly reported field size in the literature.38
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After diagnosis, patients with confirmed EoE were treated with topical corticosteroids 
(either oval viscous budesonide 1 mg twice daily or fluticasone from a multi-dose inhaler, 
880 mcg twice daily) for 8 weeks as clinically indicated.39–42 At that time, a repeat upper 
endoscopy with biopsy was performed.
Serum measures
A blood sample was obtained from all subjects before each procedure and labelled with a 
unique de-identified study number that was blinded as to case/control and treatment status. 
The sample was centrifuged and serum aliquots were separated, frozen, and stored at −80°C. 
After patient enrollment and follow-up were complete, samples were removed from the 
freezer, arranged in random order, thawed only once, and analyzed in a batch.
Serum periostin was measured by ELISA (AdipoGen, San Diego, CA; AG-45B-0004-KI01). 
Samples were run in duplicate on 96-well plates with standards and positive/negative 
controls per manufacturer instructions. IL-13 had previously been measured in the same 
patients.28
Tissue measures
In addition to the biopsy samples obtained for histopathologic assessment, additional biopsy 
samples were collected, labelled with a de-identified study number, and stored at −80°C in 
order for future use. Based on our prior study showing that gene expression was similar 
throughout the esophagus,32 this study utilized a single RNAlater (Life Technologies/
Thermo-Fisher Scientific, Grand Island, NY) preserved biopsy from the mid esophagus from 
each subject to determine tissue expression of periostin. RNA extraction was performed on 
the homogenized specimens using the RNeasy Mini Extraction Kit (Qiagen, Germantown, 
MD) using standard technique. mRNA expression was quantified by performing TaqMan 
qPCR amplification for a panel of 94 representative EoE genes and 2 housekeeping genes, as 
previously described.32, 43 For the present analysis, only periostin expression (POSTN) was 
analyzed.
Statistical analysis
Descriptive statistics were calculated for the baseline clinical, endoscopic, and histologic 
characteristics of the EoE cases and non-EoE controls. The median baseline serum periostin 
levels were compared between cases and controls using the Wilcoxon Rank-Sum test. For 
the EoE cases, median baseline and post-treatment periostin levels were compared using the 
Wilcoxon Signed-rank test. Analyses were also performed after stratification by atopic status 
(defined as the presence of either asthma, atopic dermatitis, allergic rhinitis/sinusitis, of food 
allergy) or by histologic response to treatment for the EoE cases (defined as <15 eos/hpf).4, 5 
Receiver operating characteristic curves were constructed and areas under the curve (AUC) 
were calculated to determine the utility of serum periostin for distinguishing EoE cases from 
controls at baseline. We divided EoE cases into the lowest and highest quartiles of serum 
periostin, and compared clinical, endoscopic, and histologic features, as well as serum IL-13 
levels, between these groups. We also explored periostin levels by selected clinical, 
endoscopic, and histologic characteristics. Finally, esophageal POSTN expression levels 
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were analyzed after normalization to GAPDH expression (POSTN Ct – GAPDH Ct). 
Analyses were performed with Stata 9.2 (College Station, TX).
Results
Patient characteristics
There were 61 EoE cases and 87 controls included in this study; baseline characteristics of 
these subjects have been previously described.28 Compared to controls, cases were younger 
(39 vs 52 years; p<0.001), had more dysphagia (97 vs 79%; p=0.002), less heartburn (18% 
vs 68%; p<0.001), and more atopic disorders (74% vs 53%; p=0.01). On endoscopy, typical 
features of EoE were more common in cases, including rings (74% vs 8%), narrowing (23% 
vs 2%), linear furrows (87% vs 3%), white plaques or exudates (43% vs 3%), and decreased 
vascularity or edema (59% vs 3%; p<0.001 for all). Similarly, the mean baseline eosinophil 
counts were markedly elevated in the cases compared to controls (147 vs 3 eos/hpf; 
p<0.001).
Baseline and post-treatment periostin levels
At baseline, the EoE cases had a slightly higher median baseline serum periostin level than 
controls (22.1 ng/mL [IQR 20–26] vs 20.7 [16–24]; p=0.04) (Table 1). However, the AUC 
was just 0.60 for using this marker for diagnosis of EoE. Serum periostin levels were also 
similar for cases and controls after stratification by atopic status (Table 1).
A total of 48 EoE cases had paired pre- and post-treatment serum samples that could be 
analyzed. In this subset, median baseline periostin was 22.6 (IQR 20–27) and after topical 
steroid treatment it fell slightly to 21.5 (18–3–25.1; p=0.12) (Table 1). Changes were not 
more pronounced when only examining the 27 histologic responders. In this group, baseline 
periostin was 23.0 (18–27) and post-treatment the level decreased to 21.3 (18–25; p=0.13).
Periostin, clinical features, and IL-13
Analysis of median baseline serum periostin levels in EoE cases showed that levels overall 
were similar after stratification by clinical and endoscopic features (Figure 1). However, 
there were trends towards slightly higher levels in EoE patients with atopy compared to 
those without atopy (23.3 [IQR 20–27] vs 21.0 [20–22]; p=0.08) and in EoE patients with 
esophageal narrowing compared to no narrowing (25.0 [23–28] vs 21.8 [20–25]; p=0.11). 
There were no associations between these levels and clinical features in controls (data not 
shown).
After dividing the EoE cases into quartiles based on serum periostin levels, there were no 
major clinical, endoscopic, or histologic differences between those cases in the lowest 
quartile compared to those in the highest quartile (Table 2). There was a possible trend 
towards an increased symptom duration prior to diagnosis in the high periostin group (69% 
vs 43%) but this was not significant (p=0.25). However, there was a strong trend towards 
higher median IL-13 levels in the highest quartile of EoE cases compared to the lowest 
quartile (57.1 pg/mL [IQR 1–132] vs 2.6 [0–47]; p=0.07). Additionally, in the cases with the 
highest periostin levels, there were some minor differences in periostin after treatment. For 
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the histologic responders (n = 11), median baseline serum periostin was 28.9 ng/mL (IQR: 
27.4–30.9) and this decreased to 24.9 (23.4–28.2) after treatment (p = 0.07). For the non-
responders (n = 5), median baseline serum periostin was 29.3 (28.3–32.2) and decreased to 
26.8 (23.8–29.5) after treatment (p = 0.04).
Esophageal POSTN expression
Given the few differences seen in serum periostin levels, we assessed mRNA expression of 
POSTN in our cases and controls; samples were available for 80 controls and 57 cases. 
Esophageal POSTN expression was markedly elevated in the EoE cases at baseline 
compared to controls, and decreased significantly post-treatment (Figure 2). Post-treatment 
expression was also lower in histologic responders compared to histologic non-responders. 
The correlation between baseline tissue POSTN and the baseline tissue eosinophil count was 
good (Spearman’s Rho=0.69; p<0.001). In addition, median serum IL-13 levels were higher 
in the EoE cases in the highest quartile of tissue POSTN expression compared to cases in the 
lowest quartile (64.2 pg/mL [IQR 4–151] vs 0.3 [0–37]; p=0.04).
Discussion
Given the burden of invasive testing with endoscopy and biopsy for diagnosis and 
monitoring of EoE, a non-invasive biomarker-based blood test would be of immense value. 
In this study, we analyzed the potential for serum periostin to fill this role. Periostin is one of 
the most highly upregulated genes in the EoE transcriptome20 and is involved in EoE 
pathogenesis by promoting adherence of eosinophils to fibronectin in the esophageal 
mucosa.23 Periostin is also induced by IL-1322, 23 and is more highly expressed in the 
absence of desmoglein-1.44 Therefore, it seemed to be a promising option. While we were 
readily able to measure serum periostin, found that baseline levels were slightly higher in 
EoE cases than controls at baseline, and observed slightly lower levels in EoE cases after 
treatment, these changes were not large enough to have clinical utility for either EoE 
diagnosis or monitoring of therapy. This conclusion was determined despite demonstrating 
markedly elevated tissue expression of POSTN in EoE cases. We also did not see any clear 
relation between serum periostin and clinical phenotype. However, we did see d that serum 
IL-13 levels were higher in the EoE cases with the highest levels of serum periostin and 
tissue POSTN expression.
To our knowledge, only one prior study and one abstract examined serum periostin in EoE. 
In the abstract, serum periostin levels in 23 EoE cases were quite high (mean 187 ng/mL), 
but the results cannot be directly compared with ours because they reported means and used 
a different ELISA assay; controls were not assessed.24 The other study was a randomized 
clinical trial where 17 patients received an anti-IL-13 treatment and 8 received placebo.13 At 
baseline, the mean periostin levels were approximately 91 ng/mL in the treatment group and 
80 ng/mL in the placebo group, and a modest but non-significant decrease was observed 
after treatment. However, the levels in this study may not be directly comparable to the 
levels in our study, as the investigators used liquid chromatography-mass spectrometry and 
report means, whereas we used a commercially available ELISA and report medians. The 
investigators also saw that subjects with serum periostin levels above the median had a 
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higher histologic response rate, a finding that we did not observe, though their treatment was 
with an anti-IL-13 antibody and ours was with a topical corticosteroid. This lack of change 
in the serum is in contrast to what we and others have observed with tissue expression of 
periostin, where high levels of baseline expression markedly decrease after 
treatment.13, 23, 45, 46 Interestingly, we did observe that patients with the highest periostin 
serum and tissue levels also had high levels of IL-13. This is an important confirmation in 
vivo in humans of what has previously been noted in cell lines and animal models.22, 23
While it is possible that serum levels of periostin patients in EoE do not reflect its increased 
esophageal expression, the experience with periostin in asthma might argue against this. 
Several studies,25–27, 47 though not all,48 suggest that in asthma serum periostin levels tend 
to correlate with severity of airway inflammation,25 and patients with periostin levels above 
the median for the study population have a better response to anti-IL-13 
medications.26, 27, 47 Some of these studies found median periostin levels in the same range 
as in our study (20–25 ng/mL),25, 47 but others noted higher levels (50 ng/mL).26 The 
discrepancy between the results in asthma and in EoE will require additional study to fully 
determine the utility of serum periostin in EoE.
There are several limitations of this study to consider. First, it was conducted at a single 
referral center, and the design would have been stronger if this were done as part of a clinical 
trial. However, the EoE patients seen at our site tend to have similar characteristics to other 
populations reported in the literature. Second, because this was a negative study, we cannot 
exclude the possibility of a type II error. However, this was a large sample of patients and 
the parent study was appropriately powered to assess biomarker measures.28 While it is 
possible that errors in sampling handling could explain negative results, all samples were 
collected, processed, and handled identically and there is no clear reason that degradation of 
samples would be differential between cases and controls. The ELISA assay we used is also 
likely not a cause. Though newly commercially available, the range of our serum periostin 
levels were roughly on the same order of magnitude than what has been previously reported 
in EoE and asthma;13, 47 however we cannot exclude a measurement different given the 
recent data presented in abstract form using a different ELISA.24 There are also several 
strengths of this study that lend validity to the results. We analyzed a large number of EoE 
cases and clinically relevant controls. Samples were prospectively collected using rigorous 
methodology, stored at −80°C, and only thawed once for the present analysis. Identical 
collection procedures were used for the follow-up samples. The EoE cases were a highly 
inflamed population, with demonstrated tissue elevation of periostin expression, so this 
study should have provided an optimal setting in which to detect differences in serum 
periostin.
In conclusion, in this study of a large number of prospectively collected samples from EoE 
cases and non-EoE controls, we were readily able to measure serum periostin using a 
commercially available assay. While we observed slightly higher baseline levels of serum 
periostin in EoE cases than in controls, there was no change in periostin after treatment with 
a topical corticosteroid, and overall the differences in serum periostin were not clinically 
meaningful. We also did not detect differences by atopic status or histologic response. 
However, we did find that IL-13 levels were highest in the EoE patients with the highest 
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quartile of both serum periostin levels and tissue POSTN expression. Given this observation, 
as well as the increasing data on the use of periostin to stratify asthma treatment with 
biologic therapies such as anti-IL-13 antibodies, further studies should explore the potential 
of periostin as a biomarker in similar treatment settings in EoE.
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Median periostin levels, as indicated by the diamond, for selected clinical, endoscopic, and 
histologic features in EoE cases. Interquartile ranges are noted by the dots at the end of the 
lines. All comparisons are by Wilcoxon Rank-sum.
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Tissue expression of POSTN. The GAPDH-normalized relative expression is presented on 
the y axis for controls (n = 80; black bar) and cases (n = 57; dark blue bar) at baseline, for all 
cases after treatment (n = 57; light blue bar), and for cases after treatment stratified by 
histologic response (<15 eos/hpf) status (n = 31 responders; dark green bar; and n = 25 non-
responders; light green bar). Unpaired comparisons are by Wilcoxon Rank-sum, and paired 
comparisons are by Wilcoxon Signed-rank.
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Table 1
Serum periostin levels for cases and controls, by treatment response, and by atopic status
Median periostin level (ng/mL; IQR)
Case-control analysis at baseline
  EoE cases (n = 61) 22.1 (20.0–25.9)
  Controls (n = 87) 20.7 (17.5–23.8)
  p value* 0.04
Treatment response for EoE cases (n = 48)
  Baseline 22.6 (19.6–26.7)
  Post-treatment 21.5 (18.3–25.1)
  p value† 0.12
For histologic responders among EoE cases (n = 27)‡
  Baseline 23.0 (18.4–27.4)
  Post-treatment 21.3 (18.0–25.1)
  p value† 0.13
For cases and controls with atopy#
  EoE cases (n = 45) 23.3 (20.0–27.4)
  Controls (n = 46) 21.5 (17.7–23.7)
  p value* 0.08
*
Calculated with Wilcoxon Rank-sum.
†
Calculated with Wilcoxon Signed-rank.
‡
Histologic response defined as <15 eos/hpf after treatment.
#
Atopy defined as the presence of asthma, allergic rhinitis/sinusitis, atopic dermatitis, or self-reported food allergies/sensitivities.
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Table 2






Periostin level (median ng/mL; IQR) 17.4 (15.8–16.6) 29.1 (27.7–31.4) --
Age (mean years ± SD) 38.6 ± 13.1 37.9 ± 12.7 0.87
Male (n, %) 8 (50) 3 (31) 0.47
White (n, %) 15 (94) 15 (94) 1.0
Symptoms (n, %)
  Dysphagia 16 (100) 16 (100) --
    Symptom duration > 5 years† 6 (43) 9 (69) 0.25
  Heartburn 2 (13) 4 (25) 0.65
  Abdominal pain 4 (25) 2 (13) 0.65
Any atopic disease (n, %) 12 (75) 15 (94) 0.33
  Asthma 4 (25) 6 (38) 0.70
  Rhinitis/sinusitis 11 (69) 14 (88) 0.39
  Dermatitis 1 (6) 1 (6) 1.0
  Food allergies 7 (44) 12 (75) 0.15
Endoscopic findings (n, %)
  Normal 1 (6) 0 (0) 1.0
  Rings 13 (81) 13 (81) 1.0
  Stricture 3 (19) 4 (25) 1.0
  Narrowing 3 (19) 6 (38) 0.43
  Furrows 15 (94) 14 (88) 1.0
  Crêpe-paper mucosa 0 (0) 3 (18) 0.23
  White plaques/exudates 7 (44) 9 (56) 0.72
  Edema/decreased vascularity 9 (56) 11 (69) 0.72
  Dilation performed 4 (25) 7 (44) 0.46
Eosinophil count (max eos/hpf ± SD)
  Baseline 133.4 ± 78.6 172.7 ± 156.0 0.37
  Post-treatment 23.8 ± 43.9 36.4 ± 81.8 0.59
Treatment response (n, %)‡ 11 (69) 11 (69) 1.0
Baseline IL-13 (median pg/mL; IQR)# 2.6 (0–46.7) 57.1 (1.4–132.1) 0.07
*
Fisher’s exact used for proportions, t-test used for means, Wilcoxon Rank-sum used for medians.
†
Data available for n = 27.
‡
Histologic response defined as <15 eos/hpf after treatment.
#
Data available for n = 31
Aliment Pharmacol Ther. Author manuscript; available in PMC 2017 July 01.
